CliffBio
small molecule

REDEMPLO

PLOZASIRAN SODIUM

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry
CompanyArrowhead Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameREDEMPLO
Active ingredientPLOZASIRAN SODIUM
StrengthEQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2025
Marketing statusRX

Listed patents

PatentExpiresType
12365899September 2038substance, product
11214801September 2038substance, product
10597657September 2038substance, product
10294474March 2037substance, product
11174481March 2037substance, product

Regulatory exclusivity

CodeExpires
ODE-541November 2032

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.